Fujita Health University and Hoyu Co., Ltd., known for its hair color products, have discovered a new antigen for wheat-dependent exercise-induced anaphylaxis (WDEIA).Measurement of specific IgE antibodies for this antigen is expected to greatly improve the diagnostic accuracy of WDEIA.
Wheat-dependent exercise-induced anaphylaxis (WDEIA) is a disease in which allergic symptoms do not normally occur even when wheat is ingested, but are triggered by secondary factors such as exercise or taking non-steroidal anti-inflammatory drugs. It is common in patients with a wheat allergy that develops later in life.The omega-5 gliadin-specific IgE antibody test, which is commonly used for diagnosis, shows a positive diagnosis in about 80% of WDEIA patients, but the problem was that it was not detected in about 20%. .
The newly discovered "α/β gliadin MM1"-specific IgE antibody can also be detected in the remaining approximately 20% of patients, and it is expected that by combining it with existing tests, it will be possible to diagnose many more patients who were previously undiagnosed. Ru.
“α/β gliadin MM1” was recognized as a new antigen by the World Health Organization and the International Union of Immunological Societies Allergen Nomenclature Subcommittee (WHO/IUIS), and was named “Tri a 21.0201” and was designated as an antigen in September 2023. registered in the database.
In cases of WDEIA in which ω-5 gliadin-specific IgE antibodies are negative, an "oral challenge test" is performed to confirm the onset of symptoms by exercising vigorously after ingesting wheat (combining with oral aspirin if necessary). However, the burden on the patient's body and the risks are great. The ``α/β gliadin MM1''-specific IgE antibody test is expected to avoid this burden and risk.
Currently, the ``α/β gliadin MM1''-specific IgE antibody test is not covered by insurance, but it can be performed through Hoyu Co., Ltd.'s contracted allergy analysis service.
